2021 Q2 Form 10-Q Financial Statement

#000171127921000027 Filed on August 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.799M $3.320M
YoY Change 195.15% 98.8%
% of Gross Profit
Research & Development $6.594M $3.639M
YoY Change 81.2% -13.69%
% of Gross Profit
Depreciation & Amortization $475.0K $394.0K
YoY Change 20.56% 125.14%
% of Gross Profit
Operating Expenses $16.39M $6.954M
YoY Change 135.73% 18.06%
Operating Profit -$16.39M -$6.954M
YoY Change 135.73% 18.06%
Interest Expense $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$16.36M -$6.830M
YoY Change 139.58% 27.66%
Income Tax
% Of Pretax Income
Net Earnings -$16.36M -$6.833M
YoY Change 139.47% 27.77%
Net Earnings / Revenue
Basic Earnings Per Share -$0.74 -$0.37
Diluted Earnings Per Share -$0.74 -$0.37
COMMON SHARES
Basic Shares Outstanding 22.20M shares 18.38M shares
Diluted Shares Outstanding 22.20M shares 18.38M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $367.7M $297.2M
YoY Change 23.74% 52.01%
Cash & Equivalents $329.5M $291.7M
Short-Term Investments $38.20M $5.496M
Other Short-Term Assets $2.197M $1.400M
YoY Change 56.93% 100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $369.9M $298.5M
YoY Change 23.93% 52.14%
LONG-TERM ASSETS
Property, Plant & Equipment $44.97M $15.80M
YoY Change 184.63% 165.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $21.41M $0.00
YoY Change
Other Assets $110.0K $1.436M
YoY Change -92.34% 1569.77%
Total Long-Term Assets $73.63M $19.65M
YoY Change 274.8% 119.42%
TOTAL ASSETS
Total Short-Term Assets $369.9M $298.5M
Total Long-Term Assets $73.63M $19.65M
Total Assets $443.6M $318.1M
YoY Change 39.42% 55.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.265M $1.613M
YoY Change -21.57% 80.02%
Accrued Expenses $16.50M $4.100M
YoY Change 302.49% 57.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.12M $5.800M
YoY Change 212.4% 47.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.897M $2.600M
YoY Change 165.27% -10.34%
Total Long-Term Liabilities $6.897M $2.600M
YoY Change 165.27% -10.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.12M $5.800M
Total Long-Term Liabilities $6.897M $2.600M
Total Liabilities $25.02M $8.400M
YoY Change 197.81% 22.34%
SHAREHOLDERS EQUITY
Retained Earnings -$103.4M
YoY Change
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $418.5M $309.7M
YoY Change
Total Liabilities & Shareholders Equity $443.6M $318.1M
YoY Change 39.44% 55.05%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$16.36M -$6.833M
YoY Change 139.47% 27.77%
Depreciation, Depletion And Amortization $475.0K $394.0K
YoY Change 20.56% 125.14%
Cash From Operating Activities -$10.13M -$5.060M
YoY Change 100.26% 20.48%
INVESTING ACTIVITIES
Capital Expenditures -$3.992M -$1.940M
YoY Change 105.77% 56.45%
Acquisitions
YoY Change
Other Investing Activities -$58.33M $1.000M
YoY Change -5933.2% 9900.0%
Cash From Investing Activities -$62.31M -$950.0K
YoY Change 6459.37% -23.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -195.0K 117.5M
YoY Change -100.17% 24.94%
NET CHANGE
Cash From Operating Activities -10.13M -5.060M
Cash From Investing Activities -62.31M -950.0K
Cash From Financing Activities -195.0K 117.5M
Net Change In Cash -72.64M 111.5M
YoY Change -165.17% 25.83%
FREE CASH FLOW
Cash From Operating Activities -$10.13M -$5.060M
Capital Expenditures -$3.992M -$1.940M
Free Cash Flow -$6.141M -$3.120M
YoY Change 96.83% 5.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001711279
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Local Phone Number
LocalPhoneNumber
586-5830
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
15203
dei City Area Code
CityAreaCode
412
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38210
dei Entity Registrant Name
EntityRegistrantName
Krystal Biotech, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1080209
dei Entity Address Address Line1
EntityAddressAddressLine1
2100 Wharton Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 701
dei Entity Address City Or Town
EntityAddressCityOrTown
Pittsburgh
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
KRYS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22205642 shares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
329527000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
268269000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
38203000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
2993000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2197000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3796000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
369927000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
275058000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44972000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30876000 USD
CY2021Q2 us-gaap Long Term Investments
LongTermInvestments
21411000 USD
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7136000 USD
CY2020Q4 krys Build To Suit Lease Liability Current
BuildToSuitLeaseLiabilityCurrent
7600000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3298000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
110000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1612000 USD
CY2021Q2 us-gaap Assets
Assets
443556000 USD
CY2020Q4 us-gaap Assets
Assets
310844000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1265000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2105000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
934000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
638000 USD
CY2021Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
15920000 USD
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5109000 USD
CY2021Q2 krys Build To Suit Lease Liability Current
BuildToSuitLeaseLiabilityCurrent
0 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
18119000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15452000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6897000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3308000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
25016000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
18760000 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2061773 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2061773 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22205032 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22205032 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19714220 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19714220 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
521950000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
363292000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103389000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71214000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
418540000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
292084000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
443556000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
310844000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6594000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3639000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12795000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12795000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7164000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9799000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3315000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17951000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17951000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5735000 USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
16393000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
6954000 USD
us-gaap Operating Expenses
OperatingExpenses
30746000 USD
us-gaap Operating Expenses
OperatingExpenses
12899000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16393000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6954000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-30746000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12899000 USD
CY2021Q2 krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
30000 USD
CY2020Q2 krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
121000 USD
krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
64000 USD
krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
725000 USD
CY2021Q2 us-gaap Interest Expense
InterestExpense
0 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
1492000 USD
us-gaap Interest Expense
InterestExpense
0 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6833000 USD
us-gaap Net Income Loss
NetIncomeLoss
-32174000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12174000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
16000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-27000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
30000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16387000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6817000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32201000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12144000 USD
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22204659 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22204659 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18383941 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18383941 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21731711 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21731711 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17871648 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17871648 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
292084000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
152033000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2350000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15812000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
430652000 USD
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4261000 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16363000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
418540000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
202914000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
243000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
539000 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
14000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5341000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
198369000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
117337000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
807000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
16000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6833000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
309696000 USD
us-gaap Net Income Loss
NetIncomeLoss
-32174000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12174000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1202000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
884000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
6508000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1346000 USD
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
0 USD
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-3000 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
1492000 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1366000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-378000 USD
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
0 USD
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
2400000 USD
krys Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-175000 USD
krys Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-105000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-680000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
706000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2678000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
81000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19783000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
117712000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
61258000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11281000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11281000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6462000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3454000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
38103000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
3205000 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
2959000 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
4392000 USD
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
21458000 USD
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-63064000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2267000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
152065000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
117712000 USD
krys Payments For Suit Liability
PaymentsForSuitLiability
7960000 USD
krys Payments For Suit Liability
PaymentsForSuitLiability
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
144105000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
104164000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
268269000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
187514000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
329527000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
291678000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
10143000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2675000 USD
krys Offering Costs Incurred But Not Yet Paid
OfferingCostsIncurredButNotYetPaid
36000 USD
krys Offering Costs Incurred But Not Yet Paid
OfferingCostsIncurredButNotYetPaid
132000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4060000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103400000 USD
CY2021Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
367700000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company’s policy is to invest its cash, cash equivalents and investments in money market funds, certificates of deposit, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</span></div>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1688965 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
831110 shares
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6833000 USD
us-gaap Net Income Loss
NetIncomeLoss
-32174000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12174000 USD
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22204659 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22204659 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18383941 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18383941 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21731711 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21731711 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17871648 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17871648 shares
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
28000 USD
CY2021Q2 krys Cash Cash Equivalents And Debt Securities Available For Sale
CashCashEquivalentsAndDebtSecuritiesAvailableForSale
389141000 USD
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2021Q2 krys Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost
CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
389165000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000 USD
CY2020Q4 krys Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost
CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
271255000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000 USD
CY2020Q4 krys Cash Cash Equivalents And Debt Securities Available For Sale
CashCashEquivalentsAndDebtSecuritiesAvailableForSale
271262000 USD
CY2020Q2 us-gaap Depreciation
Depreciation
394000 USD
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
48254000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33244000 USD
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3282000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2368000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44972000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30876000 USD
CY2021Q2 us-gaap Depreciation
Depreciation
475000 USD
us-gaap Depreciation
Depreciation
914000 USD
us-gaap Depreciation
Depreciation
729000 USD
CY2021Q2 krys Accrued Preclinical And Clinical Expenses
AccruedPreclinicalAndClinicalExpenses
2970000 USD
CY2020Q4 krys Accrued Preclinical And Clinical Expenses
AccruedPreclinicalAndClinicalExpenses
1735000 USD
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2119000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
642000 USD
CY2021Q2 krys Accrued Payroll And Benefits
AccruedPayrollAndBenefits
1273000 USD
CY2020Q4 krys Accrued Payroll And Benefits
AccruedPayrollAndBenefits
1486000 USD
CY2021Q2 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
22000 USD
CY2020Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
40000 USD
CY2021Q2 krys Accrued Construction In Progress Current
AccruedConstructionInProgressCurrent
9170000 USD
CY2020Q4 krys Accrued Construction In Progress Current
AccruedConstructionInProgressCurrent
1049000 USD
CY2021Q2 krys Accrued Financing Fees Current
AccruedFinancingFeesCurrent
36000 USD
CY2020Q4 krys Accrued Financing Fees Current
AccruedFinancingFeesCurrent
131000 USD
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
330000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
26000 USD
CY2021Q2 krys Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
15920000 USD
CY2020Q4 krys Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5109000 USD
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.094
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.093
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
278000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
497000 USD
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
145000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
310000 USD
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
81000 USD
CY2020Q1 krys Payment To Escrow For Reducing Lease Rentals
PaymentToEscrowForReducingLeaseRentals
2400000 USD
CY2020Q4 krys Purchase Price Of Potential Building Purchase
PurchasePriceOfPotentialBuildingPurchase
9400000 USD
CY2020Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
10000000.0 USD
CY2020Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
10000000.0 USD
CY2020Q4 krys Payment To Escrow For Reducing Lease Rentals
PaymentToEscrowForReducingLeaseRentals
2400000 USD
CY2020Q4 krys Purchase Price Of Potential Building Purchase
PurchasePriceOfPotentialBuildingPurchase
9400000 USD
CY2020Q4 us-gaap Escrow Deposit
EscrowDeposit
1500000 USD
krys Lessor Operating Lease Liability Annual Lease Payments
LessorOperatingLeaseLiabilityAnnualLeasePayments
82000 USD
krys Cumulative Escalation Clause Percent
CumulativeEscalationClausePercent
0.10
krys Cumulative Escalation Clause Term
CumulativeEscalationClauseTerm
P5Y
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
457000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1048000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1067000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1087000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1113000 USD
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
15000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
28000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
118000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
198000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
297500 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
799950 shares
CY2021Q2 krys Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
12480000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17252000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9421000 USD
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
7831000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7136000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3298000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
934000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
638000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6897000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3308000 USD
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
7831000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3946000 USD
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P15Y
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P16Y4M24D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
315400 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
544400 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
853614 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
40.31
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16804000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
799950 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
73.42
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
16874 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
21.41
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
46525 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
53.79
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1590165 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
56.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
22838000 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
253189 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
29.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M24D
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1346000 USD
CY2021Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
66000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
103000 USD
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9690000 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
808000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
872000 USD
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
656000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1200000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5840000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
CY2020Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y

Files In Submission

Name View Source Status
0001711279-21-000027-index-headers.html Edgar Link pending
0001711279-21-000027-index.html Edgar Link pending
0001711279-21-000027.txt Edgar Link pending
0001711279-21-000027-xbrl.zip Edgar Link pending
exhibit101_krystal-wtcon.htm Edgar Link pending
exhibit101_krystal-wtcon001.jpg Edgar Link pending
exhibit101_krystal-wtcon002.jpg Edgar Link pending
exhibit101_krystal-wtcon003.jpg Edgar Link pending
exhibit101_krystal-wtcon004.jpg Edgar Link pending
exhibit101_krystal-wtcon005.jpg Edgar Link pending
exhibit101_krystal-wtcon006.jpg Edgar Link pending
exhibit101_krystal-wtcon007.jpg Edgar Link pending
exhibit101_krystal-wtcon008.jpg Edgar Link pending
exhibit101_krystal-wtcon009.jpg Edgar Link pending
exhibit101_krystal-wtcon010.jpg Edgar Link pending
exhibit101_krystal-wtcon011.jpg Edgar Link pending
exhibit101_krystal-wtcon012.jpg Edgar Link pending
exhibit101_krystal-wtcon013.jpg Edgar Link pending
exhibit101_krystal-wtcon014.jpg Edgar Link pending
exhibit101_krystal-wtcon015.jpg Edgar Link pending
exhibit101_krystal-wtcon016.jpg Edgar Link pending
exhibit101_krystal-wtcon017.jpg Edgar Link pending
exhibit101_krystal-wtcon018.jpg Edgar Link pending
exhibit101_krystal-wtcon019.jpg Edgar Link pending
exhibit101_krystal-wtcon020.jpg Edgar Link pending
exhibit101_krystal-wtcon021.jpg Edgar Link pending
exhibit101_krystal-wtcon022.jpg Edgar Link pending
exhibit101_krystal-wtcon023.jpg Edgar Link pending
exhibit101_krystal-wtcon024.jpg Edgar Link pending
exhibit101_krystal-wtcon025.jpg Edgar Link pending
exhibit101_krystal-wtcon026.jpg Edgar Link pending
exhibit101_krystal-wtcon027.jpg Edgar Link pending
exhibit101_krystal-wtcon028.jpg Edgar Link pending
exhibit101_krystal-wtcon029.jpg Edgar Link pending
exhibit101_krystal-wtcon030.jpg Edgar Link pending
exhibit101_krystal-wtcon031.jpg Edgar Link pending
exhibit101_krystal-wtcon032.jpg Edgar Link pending
exhibit101_krystal-wtcon033.jpg Edgar Link pending
exhibit101_krystal-wtcon034.jpg Edgar Link pending
exhibit101_krystal-wtcon035.jpg Edgar Link pending
exhibit101_krystal-wtcon036.jpg Edgar Link pending
exhibit101_krystal-wtcon037.jpg Edgar Link pending
exhibit101_krystal-wtcon038.jpg Edgar Link pending
exhibit101_krystal-wtcon039.jpg Edgar Link pending
exhibit101_krystal-wtcon040.jpg Edgar Link pending
exhibit101_krystal-wtcon041.jpg Edgar Link pending
exhibit101_krystal-wtcon042.jpg Edgar Link pending
exhibit101_krystal-wtcon043.jpg Edgar Link pending
exhibit101_krystal-wtcon044.jpg Edgar Link pending
exhibit101_krystal-wtcon045.jpg Edgar Link pending
exhibit101_krystal-wtcon046.jpg Edgar Link pending
exhibit101_krystal-wtcon047.jpg Edgar Link pending
exhibit101_krystal-wtcon048.jpg Edgar Link pending
exhibit101_krystal-wtcon049.jpg Edgar Link pending
exhibit101_krystal-wtcon050.jpg Edgar Link pending
exhibit101_krystal-wtcon051.jpg Edgar Link pending
exhibit101_krystal-wtcon052.jpg Edgar Link pending
exhibit101_krystal-wtcon053.jpg Edgar Link pending
exhibit101_krystal-wtcon054.jpg Edgar Link pending
exhibit101_krystal-wtcon055.jpg Edgar Link pending
exhibit101_krystal-wtcon056.jpg Edgar Link pending
exhibit101_krystal-wtcon057.jpg Edgar Link pending
exhibit101_krystal-wtcon058.jpg Edgar Link pending
exhibit101_krystal-wtcon059.jpg Edgar Link pending
exhibit101_krystal-wtcon060.jpg Edgar Link pending
exhibit101_krystal-wtcon061.jpg Edgar Link pending
exhibit101_krystal-wtcon062.jpg Edgar Link pending
exhibit101_krystal-wtcon063.jpg Edgar Link pending
exhibit101_krystal-wtcon064.jpg Edgar Link pending
exhibit101_krystal-wtcon065.jpg Edgar Link pending
exhibit101_krystal-wtcon066.jpg Edgar Link pending
exhibit101_krystal-wtcon067.jpg Edgar Link pending
exhibit101_krystal-wtcon068.jpg Edgar Link pending
exhibit101_krystal-wtcon069.jpg Edgar Link pending
exhibit101_krystal-wtcon070.jpg Edgar Link pending
exhibit101_krystal-wtcon071.jpg Edgar Link pending
exhibit101_krystal-wtcon072.jpg Edgar Link pending
exhibit101_krystal-wtcon073.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
krys-20210630.htm Edgar Link pending
krys-20210630.xsd Edgar Link pending
krys-20210630ex311.htm Edgar Link pending
krys-20210630ex312.htm Edgar Link pending
krys-20210630ex321.htm Edgar Link pending
krys-20210630_cal.xml Edgar Link unprocessable
krys-20210630_def.xml Edgar Link unprocessable
krys-20210630_g1.jpg Edgar Link pending
krys-20210630_htm.xml Edgar Link completed
krys-20210630_lab.xml Edgar Link unprocessable
krys-20210630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending